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In recent years, nanomedicine has emerged at the forefront of nanotechnology area generating 
great expectations in the biomedical field. Researchers are developing novel nanoparticles for 
both diagnostic applications using imaging technology and treatment purposes through drug 
delivery technologies. Among all the available nanoparticles, inorganic mesoporous silica 
nanoparticles are the newcomers to the field contributing with their unique and superlative 
properties. In this Progress Report we provide a brief overview of the most recent progress in 
the synthesis of mesoporous silica nanoparticles and their use as drug delivery nanocarriers. 
This contribution also updates the last trends on this type of nanoparticles towards their use in 




Mesoporous Silica Materials (MSMs) were first reported by Kuroda et al. in Japan and the 
Mobil Oil scientists in USA back in the 1990s.[1],[2] Bulk mesoporous materials are produced 




precursors around them. Them, removing the template leads to a material full of network 
cavities. This new family of materials is characterized by an ordered distribution of the pores 
that present homogeneous sizes between 2 and 20 nm, high pore volume (ca. 1 cm3/g), great 
surface area (ca. 1000 m2/g) and high density of silanol groups at their surface, that might favor 
subsequent functionalization processes. These features made MSMs ideal candidates for 
applications that might require the adsorption of molecules, such as drug delivery systems, as 
proposed by the Vallet-Regí group for the first time back in 2001.[3]  
Additionally, MSMs are a type of mesostructured bioceramics that have shown bioactive 
behavior[4] thanks to the presence of silanol groups at their surface and a similar chemical 
composition to bioactive glasses.[5] Consequently, MSMs have been employed as starting 
materials for the manufacture of 3-D scaffolds for bone tissue engineering (Figure 1).[6]  
 
Figure 1. Top: schematic representation of the two main applications of mesoporous silica 
materials in biomedicine: drug delivery and bone tissue engineering. Bottom: Mesoporous 
Silica Materials are constituted of amorphous silica at atomic scale, with an ordered 




useful for bone tissue engineering. Adapted from reference [7] with permission from Walter de 
Gruyter and Company.    
 
The great textural properties of bulk MSMs and their potential biomedical applications inspired 
their translation to the nanoscale dimension.[8] Thus, a few years later, mesoporous silica 
nanoparticles (MSNs) were developed and investigated as drug delivery systems by many 
research groups Worldwide.[9],[10],[11],[12],[13] Some of the major biomedical uses proposed for 
MSNs include cancer treatment, infectious treatment and different bone diseases.[14] 
Additionally, MSNs can also be used as effective imaging agents since many types of dyes and 
contrast agents can be incorporated into the pores of MSNs.[15] 
The excellent properties of MSNs for biomedical applications have triggered the development 
of novel advanced multifunctional materials for a broad range of biotechnological applications. 
Among them, the last research breakthroughs in the biomedical area using MSNs could 
represent some of the cornerstones for future personalized treatments and diagnostic techniques 
with outstanding selectivity. In this sense, the continuous advances in nanotechnology, 
including synthesis and characterization techniques, make possible to develop nanoparticles 
able to stablish intimate interactions within the biological world. This Progress Report will 
focus on the recent developments of mesoporous silica nanoparticles and the last advances on 
their application in drug delivery technologies.    
 
2. Preparation and properties of Mesoporous Silica Nanoparticles 
Silica nanoparticles are composed of colloidal amorphous metal oxide that can be produced via 
the sol-gel method and present diameters between 50 and 300 nm. There is a variety of methods 
that can be used for the production of mesoporous silica nanoparticles but, in general terms, the 
synthetic route relays in three processes: the sol-gel process for producing silica, the use of 




modification of the Stöber method under dilute conditions to yield spherical nanoparticles. 
[10],[16],[17],[18] 
Silica nanoparticles are conventionally produced through the hydrolytic sol-gel process 
involving the hydrolysis and condensation of silicon alkoxide precursors under acidic or basic 
catalysis. As polycondensation takes place around the surfactant molecules that act as a 
template of the structure, the precursors form an oxide network that leads to a colloidal solution, 
sol, that gradually evolves towards the formation of a gel or discrete particles, depending on the 
conditions.[19] Using very dilute conditions allows obtaining monodispersed spherical silica 
particles.[20] Figure 2 illustrates the synthetic path in which the surfactant is initially dissolved 
in water at basic pH. The type of surfactant together with concentration and temperature would 
have a strong influence on the self-assembling process and, consequently, on the final 
mesostructure of the material. Then the silica precursor is added dropwise ensuring dilute 
concentration of the silica precursors. After the sol-gel process takes place, the droplets would 
gradually transform into nanoparticles Then, the surfactant template is removed through solvent 






Figure 2. Synthetic path for the synthesis of MSNs in which the surfactant molecules are 
initially dissolved in water to then add dropwise the silica precursor that would condensate 
around the surfactant template. Then, after the sol-gel process takes place and the silica 
nanoparticles are formed, the surfactant removal leads to monodispersed spherical MSNs. 
 
3. Properties of Mesoporous Silica Nanoparticles 
Mesoporous Silica Nanoparticles present well-defined and tunable physicochemical properties, 
including particle size, pore size, pore volume, surface area, volume area, pore structure and 
surface functionality. The porous structure of mesoporous silica materials provides cavities that 
can host and release a great variety of biomolecules and therapeutic agents. In fact, the 
versatility of MSNs in size, morphology and texture has fueled their application as controlled 
drug delivery nanocarriers.[21]  In this sense, MSNs can be produced with different particle 




magnetic nanoparticles embedded into their skeleton or even growing the mesoporous network 
from different metal nanoparticles cores (Figure 3).  
 
Figure 3. Transmission Electron Microscopy images of different MSNs with diverse size, 
morphology, composition and mesostructure. 1st row: longitudinal or 2D-hexagonal MSNs with 
different particle diameter (150 and 50 nm), MSNs with center radial porosity. 2nd row: Janus 
MSNs nanoparticles coated with gold nanoparticles, MSNs coated with magnetite nanoparticles 
and magnetite nanoparticles as core of MSNs. Adapted from reference [22] with permission from 
Taylor & Francis Academic Journal. 
 
The particle diameter can be tuned depending on the synthetic conditions, ranging from few 
micrometers down to few nanometers. Regarding their use as drug delivery nanocarriers, 
monodisperse nanoparticles can be prepared with sizes relevant in biological environments, 





The pore size of MSNs is a limiting factor of the molecules that could be introduced into the 
mesopores in terms of size. The pore diameter can be tuned from 2 to 30 nm depending on the 
surfactant employed as template and the synthesis conditions employed. In this sense, MSNs 
with large pore diameters (up to 50 nm) are employed for the adsorption and delivery of proteins, 
enzymes, antibodies and nucleic acids, as reviewed by Knezevic et al.[24] 
The pore volume of conventional MSNs is ca. 1 cm3/g, although Haynes et al. have been able 
to increase it up to 4.5 cm3/g.[25] The pore volume is an important factor determining the amount 
of cargo molecules that can be loaded, and MSNs are well known because of the great amount 
of molecules that can host in their network of cavities. Taking into account that drug loading is 
a surface phenomenon, the high surface area of MSNs ensures the great loading capability of 
this type of nanocarriers, as it has been mentioned above, sometimes even exceeding 35 
wt.%.[26]  
Different porous morphologies and textures for MSNs have been reported, such as MCM-41-
like hexagonal, cubic, concentric, foam-like, radial, or worm-like porosity. In fact, it has been 
reported that controlling the morphology of the MSNs pores permits to selectively load different 
molecules of various sizes and, similarly, tune the cargo release together with the matrix 
dissolution kinetics.[23] 
As it has been mentioned above, adsorption is a surface phenomenon that is strongly influenced 
by the potential host-guest interaction. In this regard, the chemistry of the surface of MSNs 
could be easily tuned thorough the functionalization of the silanol groups located at the surface 
of the matrices. The literature has described many surface modification strategies to covalently 
attach almost any functional group.[27] Thus, the host-guest interaction can be designed as 







4. Safety and Biodegradation of MSNs 
Despite all the scientific publications and interest on mesoporous silica nanoparticles, MSNs 
have not been approved by the Food and Drug Administration (FDA) for use in medical 
applications. To achieve that, it is important to address the possible biodistribution, clearance 
routes and the final fate of these nanoparticles in the body.[28] In general, the performance of 
any material is dependent on the rate and extent of Adsorption, Distribution, Metabolism and 
Elimination (ADME). From the nanotechnology point of view, those processes are included 
into biokinetics, which include uptake, biodistribution and elimination.[29]  
The most common routes of administration of nanoparticles for drug delivery are intravenous, 
subcutaneous, and intratumoral injections. The benefits of injecting the nanoparticles into the 
blood stream include the rapid delivery and distribution throughout the vasculature. However, 
the stability of those nanoparticles in physiological media is an important requirement to use 
them through the bloodstream. In this sense, it is very important that the nanocarriers might be 
robust enough from the chemically point of view to protect the loaded cargo during the journey. 
Then, it could also be desirable that the carriers might degrade upon accomplishing their 
mission. Therefore, it is essential to understand the potential lixiviation rate of MSNs in 
physiological fluids to control the release kinetics and the cytotoxicity. MSNs consist of a SiO2 
matrix that could be susceptible to nucleophilic attack by OH from water in aqueous media, 
leading to the hydrolytic breakdown of the network and orthosilicic acid as by-product, which 
is biocompatible and excreted through the urine. In this sense, the degradability of MSNs is 
governed by the dissolution mechanism of silica particles into silicic acid in biological 
media.[23] This acid is soluble in water and contributes to maintain bone health, so silica has 
been recognized as safe by the FDA for over 50 years.[21] The dissolution rate of MSNs depends 
on the particle characteristics (such as surface area, pore size, condensation degree, 
functionalization, etc.) and on the degradation medium characteristics (pH, temperature, 




weeks, depending on the final application. In this sense, the incorporation of different additives, 
both organic or inorganic, can modify the dissolution rate of MSNs. Examples include the 
noncovalent incorporation of organic molecules, such as photosensitizers[30] or anticancer 
drugs,[31] or inorganic moieties such as zirconium,[32] calcium,[33] manganese or iron.[34] 
On the other hand, the covalent incorporation of organic moieties has not only modified the 
degradation kinetics of MSNs, but has created a new category of mesoporous nanoparticles so-
called periodic mesoporous organosilicas (PMOs).[35] This new type of materials share similar 
synthetic protocols and framework with MSNs, but they can offer totally different properties, 
including degradation rates, thanks to the great versatility of different organic molecules that 
can be introduced within the mesostructure. Thus, PMOs could be quite relevant for future 
clinical applications of mesoporous silica nanoparticles.[23] In this sense, different organic 
moieties were found to protect the mesoporosity for long periods of time,[36] as many studies 
on degradation kinetics have demonstrated, such as ethylene-curcumin-bridged PMS 
nanospheres,[37] ethylene-bridged PMO with a rod-like morphology[38], phenylene-bridged 
PMO nanospheres,[39] and other degradable organic derivate that have been incorporated into 
PMOs.[21] Among them, cleavable organic moieties such as disulfide,[40] tetrasulfide,[41] 
oxamide[42] and lysine[43] have been incorporated within the framework of PMO nanoparticles 
for tuning the degradability kinetics on demand. 
The in vitro degradation process on MSNs in relevant physiological media has been previously 
investigated,[44] finding that the intrinsic characteristics of MSNs remain stable long enough to 
guarantee their functionality as drug delivery nanocarriers. As commented above, the main 
factors governing the MSNs degradation under relevant physiological conditions were found to 
be the surface area, morphology, the chemical composition (potential functionalization of the 
nanoparticles surface) and the loaded cargo, among others.[45]  On the other hand, the in vivo 




most of the cases, the surface functionalization of the nanoparticles with polymeric coatings 
has improved the stability and increased the bloodstream circulation time.   
The biodistribution of MSNs has been explored only in small animals, confirming the MSNs 
accumulation in the reticuloendotelial system (RES), which include lungs, liver, and spleen.[46] 
That accumulation into the RES organs has been attributed to the adsorption of serum proteins 
onto nanoparticles, and this is why MSNs have been typically functionalized with hydrophilic 
polymers like poly(ethylene glycol) (PEG). However, it has recently been found that those 
adsorbed proteins can somehow enhance the cellular selectivity of targeted MSNs,[47] which is 
indicative that the composition of the protein corona can influence the biodistribution of the 
nanoparticles. In this sense, the required surface modification of MSNs would also influence 
on the protein corona and, consequently, on the biodistribution of those nanoparticles in 
comparison to unmodified MSNs. 
Biodistribution of MSNs has been evaluated after radiolabeling MSNs with positron emission 
tomograpfy (PET) detectable 64Cu using BALB/c mice bearing xenografts of murine breast 
cancer tumors[48] and nude mice beating xenografted human glioblastoma tumors.[49] The 
biodistributions were observed to be similar in both approaches regardless of the presence of a 
targeting ligand or not. The liver presented the highest concentration of nanoparticles while low 
MSNs concentration was observed in lung, spleen, kidney and intestines. Additionally, the 
particle concentration in the blood remained relatively low. These studies demonstrated almost 
identical biodistribution independently of the different animal models employed. Similar 
biodistribution experiments with different labelling elements such as 89Zr and 45Ti with different 
particle diameter led to the conclusion that increasing particle size from 80 to 160 nm promoted 
higher accumulation in the spleen than in the liver.[50][51] Same size of MSNs (80 nm) but 
different labelling (fluorescent due) were employed for evaluating the biodistribution on tumor-
free mice.[52] In this case, the highest amount of MSNs was found in the spleen, but particles 




functionalization on biodistribution was also evaluated. MSNs functionalized with PEG 
presented longer blood circulation time regardless of the particle size, as expected. However, 
larger nanoparticles presented much shorter blood circulation time, presumably because of their 
accumulation in the liver and the spleen. A similar effect of MSNs functionalized with PEG 
and labelled with 89Zr was observed in mice xenografted with LNCaP and PC-3 tumors. The 
non-PEGylated particles were rapidly accumulated in lung, liver and spleen while PEG-MSNs 
presented much longer blood circulation time.[53][54] When MSNs were functionalized with 
cationic species, such as amine groups, a quick accumulation in the liver was observed, which 
could be explained by the fast protein adsorption onto the cationic surface of MSNs.[55][56] 
Besides the size and surface functionalization, the particle shape has also shown a strong 
influence on the biodistribution of MSNs. In this sense, spherical and elongated MSNs have 
been studied, finding that elongated and cylindrical particles tend to accumulate in the spleen 
and present shorter blood circulation time as compared to spherical particles.[55][57][58] 
Regarding the clearance of MSNs from the body, different studies have confirmed that renal 
elimination is the main excretion route for this type of nanoparticles.[23][57] Among those studies, 
a seminal investigation by Tamanoi and coworkers demonstrated that MSNs were initially 
observed in the spleen and in the liver, but most of them were renally excreted after 96 hours, 





Figure 4. Toxicity evaluation of MSNs injected intravenously in 12 female mice twice per 
week for 14 days. Left: Top left corner: average body weights; bottom left corner: 
representative tissue sections of mice stained with hematoxylin and eosin; Top right corner: two 
groups of mice were administered MSNs at a dose of 1 mg per mouse or saline solution, in the 
plot the average body weights; bottom right corner: representative tissue sections of mice 
stained with hematoxylin and eosin. Right: analysis of the Si concentration in urine and feces 
of mice collected after injection of MSNs. Adapted from ref. [59] with permission from John 
Wiley and Sons.    
 
Although partial particle dissolution was assumed to be necessary for renal clearance,[60] many 
reports have found intact MSNs with sizes larger than 90 nm in the urine,[57][59][61] and no 
mechanisms have been proposed for this observation. 
Regarding other excretion routes, hepatobiliary excretion through the liver and bile is governed 
by protein adsorption[62] and excretion through the feces has been observed to be favored by 
aggregation of small particles.[63] 
There is an interesting connection between the blood circulation time of MSNs and the 
excretion route.[64] The longer is the blood circulation time, typical for PEGylated MSNs, the 
slower is the clearance rate. Additionally, the PEG chains grafted on the surface of MSNs can 
slow their dissolution rate, which also helps to delay their clearance.[65] 
 
4. MSNs as smart drug delivery systems 
The reasons for the great success of MSNs as drug delivery systems relays on their above 
mentioned physical-chemical properties. In fact, MSNs can provide a novel therapeutic 
armamentarium capable of addressing some of the main pitfalls of conventional medicine, such 




low drug solubility and/or stability, adverse pharmacokinetic profiles and some possible side 
effects.  
In general, any nanoparticle employed as a drug delivery system, should fulfill some basic 
requirements, as described in Figure 5, such as loading the maximum amount of cargo 
molecules, releasing the cargo on-demand avoiding premature release, reaching the diseased 
tissue to release the cargo only where needed and, in case of cancer treatment, penetrate deep 
into the tumor. 
 
Figure 5. Representative roadmap for a MSNs platform to reach the preclinical studies, 
including the synthesis of the MSNs, demonstration of their stability, therapeutic cargo loading 
into the pores, Quality Assurance or characterization the loaded platform, smart release 
behavior, penetration into tumor mass, cellular uptake and in vivo evaluation. Adapted from 






4.1 Loading and protecting the therapeutic cargo 
There are two different ways of loading drugs into MSNs, in situ during the synthetic path or 
post-sorption (physisorption or chemisorption).[15] One of the benefits of the later is that 
involves a separate step following particle synthesis, which allows independent optimization of 
loading conditions. The most common approaches involve physical adsorption from solution 
into the mesopores, physical adsorption from solution onto the outer surface and covalent 
grafting. In any case, the high surface area and pore volume of MSNs ensure higher drug 
loadings than other type of nanoparticles, as mentioned above. This allows using fewer 
nanoparticles of MSNs than other nanocarriers for the potential treatment of the same disease, 
which might be of importance regarding potential toxicity issues. 
An additional benefit of using MSNs as drug carriers is that cargo molecules loaded inside the 
mesopores will be protected from tough environmental factors within living systems such as 
enzymatic degradation or harsh pH. In fact, silica is an inorganic compound that can provide 
efficient protection of different types of encapsulated molecules.[67]  Up to 2010, the location 
of cargo molecules in mesoporous materials was deduced from the sum of indirect techniques, 
such a nitrogen adsorption, Fourier transformed infrared spectroscopy, X-ray fluorescence 
spectroscopy, elemental analysis and/or thermogravimetry. However, the use of electronic 
microscopy allowed the direct evidence of the drug confinement into the inner part of the pore 
channels back in 2010.[68] Scanning Transmission Electron Microscopy (STEM) with spherical 
aberration correctors incorporated permitted the determination of the chemical composition of 
matrix network and pores (Figure 6). This microscopy technique is based on scanning the 
material with an electron probe that can be focused down to 1 nm or less on the sample. 
Afterwards, the STEM images can be formed with the collected scattered electrons in each 
probe position by the high-angle annular dark-field detector in synchronism with the scanning 
probe. This technique enables to perform analyses with enough resolution capable of atomic 




pore space where the cargo molecules are confined. Consequently, this technology allowed for 
the first time the confirmation that the cargo molecules were actually into the inner area of the 
mesopores.  
 
Figure 6.  Schematic representation of the different possibilities for drug delivery technologies 
offered by MSNs (left), and Transmission Electron Microscopy images of MSNs from different 
perspectives where silica wall and mesopores (top right) and drug loaded pore entrances 
(bottom right) can be observed. Adapted from reference [68] with permission from the Royal 
Society of Chemistry. 
 
4.2 Release therapeutic cargo on-demand 
An ideal nanocarrier should be able to release high local concentrations of the therapeutic cargo 
on-demand after the application of a stimulus, leading to smart drug delivery systems.[69] One 




the transported cargo before reaching the targeted tissues, which improves the nanomedicine 
efficiency and reduces potential side effects if the cargo might be cytotoxic.  
This stimuli-responsive approach is of particular interest for MSNs because of their peculiar 
and unique textural characteristics. It is relatively easy to introduce a therapeutic cargo inside 
the mesopores of MSNs, although it might also be very easy for those cargo molecules to diffuse 
out of the mesoporous channels. It is then necessary to close the pore entrances with a cap once 
the cargo is loaded inside the mesoporous network of cavities. The pore diameter of MSNs 
allows using large molecules to block the pore entrances. Only upon the application of certain 
stimuli, those cap agents would detach from the pore entrances triggering the cargo on-demand. 
Those capping systems can be divided into three main groups: reusable caps, based on a bulky 
capping molecule able to bind reversibly; completely reversible caps, based on the principle of 
reversal affinity of a ring shaped macromolecule into a steam with two or more binding sites: 
and, irreversible caps, based on a chemical bond cleavage of the capping molecule which leads 
to a permanent separation from the pore entrance of the MSN.[70] 
There are two main types of stimuli that have been widely employed for triggering the 
therapeutic cargo release from MSNs: internal and external stimuli, as it can be observed in 







Figure 7. Schematic representation of stimuli-responsive MSNs that can be triggered with both 
internal or external stimuli to release the therapeutic cargo. Adapted from reference [7] with 
permission from Walter de Gruyter and Company.    
 
Internal stimuli are those typical of the treated pathology, and the subsequent responsive MSNs 
are able to respond to chemical variations that take place in certain sites of the human body as 
a consequence of the differences between diseased and healthy organs and/or tissues.  
Among the internal stimuli, pH is probable the most widely employed internal stimulus to 
trigger the cargo release from MSNs.[81],[82],[83],[84],[85],[86],[87],[88],[89],[90],[91],[92] The reason for that 
is because there are several pathologies that present different pHs than those of healthy 
conditions, such as extracellular pH of tumor tissues or the pH of inflamed tissues. There are 
also differences on the pH values inside the cells, depending on the cell compartment or 
organelle. The dysregulation of certain enzymes and/or specific antibodies, both hypo- or 
overexpression, in certain pathological states or diseased tissues can also be used for triggering 
the therapeutic cargo release from MSNs.[93],[94],[95],[96],[97],[98],[99],[100],[101],[102] Similarly, the 
change in redox potential as it happens in tumor tissues where the glutathione concentration 





On the other hand, external stimuli are those than can be activated remotely by the clinician, 
who is under control at all times. One of the benefits of this type of responsive nanocarriers is 
that the release can be turned on and off as required, which might lead to pulsatile responsive 
release systems. Additionally, some stimuli can be applied locally into the site of the disease, 
which increase the precision of the treatment improving the efficacy and efficiency. 
The use of magnetic fields for triggering the cargo release from MSNs has been very popular 
because they allow magnetic guidance under a permanent magnetic field or temperature 
increase upon the application of an alternating magnetic field. This permits developing MSNs 
with a wide range of possibilities in the biomedical field. [9],[113],[114],[115],[116],[117],[118],[119],[120] 
Ultrasounds is also an external stimulus that constitutes an efficient element for developing 
responsive MSNs with spatiotemporal control of the cargo delivery at the target site and 
preventing the damage of the healthy tissues.[121],[122],[123],[124],[125] Some of the benefits of 
Ultrasounds include its non-invasiveness, the absence of ionizing radiations and the easily 
regulation of tissue penetration depth by tuning some basic parameters.  
Light also constitutes a useful alternative for developing externally triggered MSNs with non-
invasive and spatiotemporal control of the release.[126],[127],[128],[129],[130],[131],[132],[133],[134] In this 
case, the wavelength of the radiation can be selected from different regions, such as ultraviolet, 
visible or near infrared (NIR). Some of the advantages of using light as stimulus relies on its 
easy application, low toxicity and precise focalization at the targeted tissue. However, the major 
pitfall relays on the low tissue penetration capability, which forces to use medical devices as 
those used for laparoscopic surgery. A possible alternative could be the use of two-photon-
excited nanomedicine in the NIR, which allow imaging and therapy of small tumors that might 
be detected at an early stage. In fact, many cancers could be targeted using two-photon 
excitation strategies, such as retinoblastoma, prostate cancer, breast cancer or colon cancer.[135] 
Since the first drug delivery system based on MSNs for two-photon adsorption  using coumarin 




and physics has allowed  many efficient two-photon absorbers and photosensitizers.[40][137] 
Subsequently, many different versatile two-photon-triggered systems based on MSNs have 
been designed for the delivery of reactive oxygen species, drugs and genes to efficiently kill 
cancer cells.[138][139][140][141][142][143][144]   
 
4.3 Transporting the therapeutic cargo to the right place 
One of the key aspects for a nanocarrier, regardless of the type of nanoparticles, is to transport 
huge loads of therapeutic molecules to precise locations in the body for disease treatments with 
enhanced efficacy and reduced side effects. In this sense, it should be compulsory to look at the 
biological behavior of MSNs taking into account their biocompatibility, biodistribution, 
biodegradability and clearance. 
As it has been mentioned above, the biocompatibility of MSNs has been evaluated in many 
studies, and it was found that toxicity might depend on several characteristics, such as size, 
shape, surface chemistry and surface charge.[67] After many different studies investigating the 
effect of the size,[59],[52],[145],[146],[147]  it was found that relatively small MSNs could be 
considered as potentially safe candidates for biomedical applications. Nanoparticles smaller 
than 10 nm would undergo fast renal clearance, while nanoparticles larger than 300 nm could 
provoke embolisms due to their possible aggregation into capillaries and alveoli.  
The shape effect was also evaluated using rods and spherical MSNs,[57] finding that MSNs 
shape might have an strong influence in cell interaction and biodistribution. Although spherical 
MSNs have been traditionally employed in nanomedicine due to their relatively easy fabrication 
process, rod-like MSNs present different accumulation tissues, and cellular 
internalization.[58],[148] 
The surface of MSNs governs the interaction of the nanoparticles with the physiological 
environment, so both the chemical composition and the surface charge are of capital importance. 




to surface silanolates and/or silica reactive oxygen species generation.[12] Generally, MSNs are 
decorated with non-toxic hydrophilic polymers such as PEG to increase the blood circulation 
time and to enhance the stability in physiological fluids. The PEG layer prevents the non-
specific protein adsorption which could trigger the immune response. Additionally, the 
functionalization of MSNs with PEG helps to avoid particle aggregation, which is very 
important to ensure the biocompatibility of this platform.  
Many different groups have investigated the biodistribution of MSNs in animal models. In this 
sense, MSNs with different sizes and PEG functionalities were injected in healthy mice 
observing that pegylation favored the blood circulation time as the particles escaped from 
phagocytosis.[52] Basically, MSNs and pegylated MSNs accumulated in the liver and spleen 
after intravenous administration into healthy animals.   
Most of the research on MSNs for drug delivery has been focused on the potential treatment of 
cancer. Therefore, it is of capital importance that those nanocarriers might accumulate in tumor 
tissues to release their cargo in there. In this sense, it is well known that nanoparticles leak into 
tumor when injected into the blood stream. The reason for that preferential accumulation in the 
tumor tissue, also called passive targeting, can be found in the particular blood vessel 
architecture of the tumor, which present wide fenestrations. Furthermore, tumor tissues usually 
lack effective lymphatic drainage, and this is why this preferential accumulation phenomenon 
is known as Enhanced Permeability and Retention (EPR) effect.[149] This effect has been 
exploited to increase the preferential accumulation of MSNs in mice affected by human cancer 
xenografts.[59],[150],[151],[56]   
However, in certain cases the EPR effect offers smaller nanoparticle accumulation than initially 
expected, which might result in therapeutic concentrations that might not be good enough for 
treating some cancers.[152] A potential alternative to increase the nanoparticle accumulation into 
tumor tissue consists on decorating the surface of the nanoparticles with certain ligands that 




cells.[153] This targeting strategy, known as active targeting, has been employed by several 
research groups to increase the accumulation of MSNs into tumors using, among others, folate 
or peptides as targeting agents.[154],[61],[155],[156],[157],[139],[48]  In this sense, it has been found that 
the combination of both passive and active targeting produce much better results in terms of 
therapeutic cargo selective accumulation when employed together. Figure 8 describes the work 
for developing a novel targeting agent for the selective treatment of neuroblastoma, which is 
the most frequent extra cranial pediatric tumor.[158] The combination of active and passive 
targeting approaches ensured a significant accumulation within the tumor mass after 48 and 72 




Figure 8. Schematic representation of the combination of active and passive targeting 
approaches (top) and the subsequent nanocarriers accumulation into tumor tissue resulting from 





It is also possible to develop a multi-targeted delivery system in terms of targeting tissues and 
cells with the same platform. In this case, the cell-organelle targeting might be of interest for 
the treatment of multidrug resistant tumors. MSNs technology permits developing a 
multifunctional two-drug double vectored nanocarriers though the assembly of different layers 
of functional building blocks. This system allows a sequential cell-organelle targeting of two 
different therapeutic cargoes.[159] A similar double-targeting approach was used for the 
diagnosis and treatment of neuroblastoma.[160] In this case, a family of novel scaffolds with 
structural analogues of meta-iodo-benzilguanidine, which presents a strong affinity towards 
norepinephrine transporter overexpressed on the membrane of neuroblastoma cells.   
 
4.4 Tumor penetration 
Once the nanocarriers might have reached the targeted tissue of a solid tumor thanks to both 
passive and active targeting, they would find an additional problem. Tumor mass is normally 
constituted of a mixture of cancer cells, blood vessels and dense extracellular matrix. The high 
density of that matrix, normally higher than in healthy tissues, together with the elevated 
interstitial pressure of solid tumors, hinders the penetration of the nanocarriers limiting their 
therapeutic efficacy to the peripheral sites of the tumor.[161] A potential solution that has been 
explored is based on using proteolytic enzymes attached to the surface of nanoparticles to 
degrade the tumor matrix and, therefore, open the way to the nanocarriers to reach deeper areas 
of the tumor.[162] However, those enzymes could suffer from degradation during their way to 
the tumor, so it is possible to develop MSNs with protected proteolytic enzymes grafted at their 
surface. The designed platform was based on acid-degradable nanocapsules of collagenase that 
were formed with a pH-degradable cross-linker. Thus, when exposed at acid pH, which are 
typical from tumor tissues as a consequence of lactic acid accumulation, the enzymatic 
protection was degraded and the enzyme exposed powering the penetration deep into the tumor 




recently evaluated as a mechanism to induce MSNs extravasation and penetration to a tumor 
mass.[164] Using an in vitro flow-through agarose tissue phantom MSNs were observed to 
extravasate into the agarose gel when Ultrasound was applied at pressures beyond the internal 
cavitation threshold, which could be applied to a real tumor tissue in the near future.    
 
5. Conclusions and Outlook 
In this Progress Report we have revised the origins of mesoporous silica nanoparticles together 
with their synthetic protocols and properties that made them suitable to be used as drug delivery 
nanocarriers. These MSNs are unique nanoparticles that combine the chemical and physical 
stability of silica and the potential offered by the network of cavities from the mesoporous 
structure. In fact, the unique properties of MSNs, such as their great loading capability, their 
controllable particle size and shape, their suitability for an easy functionalization and their 
biocompatibility, have made them ideal candidates to be used as therapeutic nanocarriers. 
Regarding the roadmap that MSNs should follow to reach clinical trials, from our point of view, 
there are some important challenges that need to be fulfilled before clinical translation can be 
achieved. Among others, it is important to standardize the production protocols to achieve 
reproducibility in the synthesis of MSNs; it is also very important that the produced 
nanoparticles should display the appropriated stability and dispersibility; any surface 
functionalization method should also be standardized before reaching the clinic. More 
importantly, more biodistribution studies of MSNs on different animal models should be carried 
out to be absolutely sure of what would be the final fate of the MSNs. 
From a general perspective, it is evident that there has been a huge progress in the design and 
development of MSNs for biomedical applications, as we have reflected in this Progress Report. 
However, it is obvious that a large amount of work still needs to be done before clinical 
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